Empiricism in managing behçet's syndrome

Clinical and Experimental Rheumatology

Volumn 30, Issue SUPPL.72, 2012, Pages

  Yazici, Hasan ^a   Hatemi, Gulen ^a  

^a ISTANBUL UNIVERSITY   (Turkey)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; ANTICOAGULANT AGENT; AZATHIOPRINE; BENZATHINE PENICILLIN; COLCHICINE; CYCLOSPORIN A; GLUCOCORTICOID; INFLIXIMAB; METHOTREXATE; PLACEBO; STEROID; TUMOR NECROSIS FACTOR ALPHA INHIBITOR; IMMUNOSUPPRESSIVE AGENT;

BEHCET DISEASE; CENTRAL NERVOUS SYSTEM DISEASE; CHRONIC DRUG ADMINISTRATION; COMBINATION CHEMOTHERAPY; DISEASE SEVERITY; DRUG CHOICE; DRUG EFFICACY; EDITORIAL; EMPIRICISM; EVIDENCE BASED MEDICINE; GENITAL ULCER; HUMAN; LUNG EMBOLISM; MONOTHERAPY; MOUTH LESION; PRIORITY JOURNAL; PUSTULE; RETINA MACULA CYSTOID EDEMA; RETINA NEOVASCULARIZATION; RETINA VASCULITIS; RETINITIS; RHEUMATOID ARTHRITIS; THROMBOPHILIA; TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT; UVEITIS; VEIN THROMBOSIS; CLINICAL PRACTICE; NOTE;

ANTICOAGULANTS; BEHCET SYNDROME; HUMANS; IMMUNOSUPPRESSIVE AGENTS; PHYSICIAN'S PRACTICE PATTERNS;

EID: 84873256930     PISSN: 0392856X     EISSN: 1593098X     Source Type: Journal    
DOI: None     Document Type: Editorial

References (22)

1. WAKEFIELD D, CUNNINGHAM ET JR, TUGAL-TUTKUN I, KHAIRALLAH M, OHNO S, ZIERHUT M. Controversies in Behçet disease. Ocul Immunol Inflamm 2012; 20: 6-11.
2. YAZICI H, TÜZÜN Y, PAZARLI H et al. Influence of age of onset and patient's sex on the prevalence and severity of manifestations of Behçet's syndrome. Ann Rheum Dis 1984; 43: 783-9.
3. HAMURYUDAN V, HATEMI G, TASCILAR K et al. Prognosis of Behçet's syndrome among men with mucocutaneous involvement at disease onset: long-term outcome of patients enrolled in a controlled trial. Rheumatology (Oxford) 2010; 49: 173-7.
4. KURAL-SEYAHI E, FRESKO I, SEYAHI N et al. The long-term mortality and morbidity of Behçet syndrome: a 2-decade outcome survey of 387 patients followed at a dedicated center. Medicine (Baltimore) 2003; 82: 60-76.
5. KURTUNCU M, TUZUN E, MUTLU M et al. Clinical patterns and course of Neuro-Behçet's disease: analysis of 354 patients comparing cases presented before and after 1990. Clin Exp Rheumatol 2008; 26 (Suppl. 50): S17.
6. AHN JK, LEE YS, JEON CH, KOH EM, CHA HS Treatment of venous thrombosis associated with Behçet's disease: immunosuppressive therapy alone versus immunosuppressive therapy plus anticoagulation. Clin Rheumatol 2008; 27: 201-5.
7. DESBOIS AC, WECHSLER B, RESCHE-RIGON M et al. Immunosuppressants reduce venous thrombosis relapse in Behçet's disease. Arthritis Rheum 2012; 64: 2753-60.
8. UZUN O, AKPOLAT T, ERKAN L. Pulmonary vasculitis in Behçet disease: a cumulative analysis. Chest 2005; 127; 2243-53.
9. LAKHANPAL S, TANI K, LIE JT, KATOH K, ISHIGATSUBO Y, OHOKUBO T Pathologic features of Behçet's syndrome: a review of Japanese autopsy registry data. Hum Pathol 1985; 16: 790-5.
10. HAMURYUDAN V, OZ B, TÜZÜN H, YAZICI H The menacing pulmonary artery aneurysms of Behçet's syndrome. Clin Exp Rheumatol 2004; 22 (Suppl. 34): S1-3.
11. SEYAHI E, MELIKOGLU M, AKMAN C et al. Pulmonary artery involvement and associated lung disease in Behçet disease: a series of 47 patients. Medicine (Baltimore) 2012; 91: 35-48.
12. AKTULGA E, ALTAÇ M, MÜFTÜOGLU A et al. A double blind study of colchicine in Behçet's disease. Haematologica 1980; 65: 399-402.
13. YURDAKUL S, MAT C, TÜZÜN Y et al. A double-blind trial of colchicine in Behçet's syndrome. Arthritis Rheum 2001; 44: 2686-92.
14. DAVATCHI F, SADEGHI ABDOLLAHI B, TEHRANI BANIHASHEMI A et al. Colchicine versus placebo in Behçet's disease: randomized, double-blind, controlled crossover trial. Mod Rheumatol 2009; 19: 542-9.
15. HATEMI G, SILMAN A, BANG D et al. EULAR recommendations for the management of Behçet disease. Ann Rheum Dis 2008; 67: 1656-62.
16. KÖTTER I, HAMURYUDAN V, OZTÜRK ZE, YAZICI H. Interferon therapy in rheumatic diseases: state-of-the-art 2010. Curr Opin Rheumatol 2010; 22: 278-83.
17. PIPITONE N, OLIVIERI I, SALVARANI C. Recommendations of the Italian Society of Rheumatology for the treatment of the primary large-vessel vasculitis with biological agents. Clin Exp Rheumatol 2012; 30 (Suppl. 70): S139-61.
18. DEUTER CM, ZIERHUT M, MÖHLE A, VONTHEIN R, STÖBIGER N, KÖTTER I. Long-term remission after cessation of interferon-α treatment in patients with severe uveitis due to Behçet's disease. Arthritis Rheum 2010; 62: 2796-805.
19. MARKOMICHELAKIS N, DELICHA E, MASSELOS S, FRAGIADAKI K, KAKLAMANIS P, SFIKAKIS PP. A single infliximab infusion vs corticosteroids for acute panuveitis attacks in Behçet's disease: a comparative 4-week study. Rheumatology (Oxford) 2011; 50: 593-7.
20. YAMADA Y, SUGITA S, TANAKA H, KAMOI K, KAWAGUCHI T, MOCHIZUKI M Comparison of infliximab versus ciclosporin during the initial 6-month treatment period in Behçet disease. Br J Ophthalmol 2010; 94: 284-8.
21. ARIDA A, FRAGIADAKI K, GIAVRI E, SFIKAKIS PP Anti-TNF agents for Behçet's disease: analysis of published data on 369 patients. Semin Arthritis Rheum 2011; 41: 61-70.
22. YAZICI H: Use and abuse of the controlled clinical trial. Bull NYU Hosp Jt Dis 2007; 65: 132-4.